Breast cancer metastases to cerebellum.
http://meetinglibrary.asco.org/content/125957-144
[this predates the release of Perjeta]
"approximately 10% of [all] breast cancer (BC) patients develop metastases to cerebellum"
"Her2 over-expression was higher than expected (13/18;72,2%)"
" Majority (11/18; 61%), developed cerebellar metastases as a resectable, first metastatic site, and 73% (8/11) of these patients had Her2 3+ BC, treated with trastuzumab. Our results suggest that Her2 3+ BC has a greater propensity to metastasize to cerebellum than Her2 negative BC."